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Tetrahydrobiopterin is a limiting factor of nitric oxide generation
in interleukin 1-stimulated rat glomerular mesangial cells
HEIK0 MUHL and JOSEF PFEILSCHIFTER
Department of Pharmacology, Biozentrum, University of Base4 Base!, Switzerland
Tetrahydrobiopterin is a limiting factor of nitric oxide generation in
interleukin lfl-stimulated rat glomerular mesangial cells. Treatment of
mesangial cells with recombinant human interleukin 113 (IL-113) triggers
the expression of a macrophage-type of nitric oxide (NO) synthase and the
subsequent increase of cellular concentration of cOMP and nitrite pro-
duction. Tetrahydrobiopterin (BH4) is an essential cofactor for NO
synthase, and in the present study we investigated its impact on inducible
NO synthesis in mesangial cells. Inhibition of GTP-cyclohydrolase I, the
rate-limiting enzyme for BH4 synthesis, with 2,4-diamino-6-hydroxy-py-
rimidine (DAHP) potently suppresses IL-1f3-induced nitrite production
and elevation of cellular cOMP levels. This inhibitory effect of DAHP is
reversed by sepiapterin, which provides BH4 via the pterin salvage
pathway. Most importantly, sepiapterin dose-dependently augments IL-
113-stimulated NO synthesis, indicating that the availability of BH4 limits
the production of NO in cytokine-induced mesangial cells. N-acetylsero-
tonin, an inhibitor of the BH4 synthetic enzyme sepiapterin reductase,
completely abolishes IL-1fi-stimulated nitrite production, whereas meth-
otrexate, which inhibits the pterin salvage pathway, displays only a
moderate inhibitory effect, thus suggesting that mesangial cells predomi-
nantly synthesize BH4 by de novo synthesis from G1'P. In conclusion, these
data demonstrate that BH4 synthesis is an absolute requirement for, and
limits IL-1f3 induction of NO synthesis in mesangial cells. Inhibition of
BH4 synthesis may provide new therapeutic approaches to the treatment
of pathological conditions involving increased NO formation.
The synthesis of NO from L-arginine by NO synthase is an
important intracellular and intercellular signalling pathway origi-
nally discovered in macrophages and endothelial cells [1, 2].
Molecular cloning and sequence analyses revealed the existence
of at least three main types of NO synthase isoforms. The brain
and endothelial enzymes are constitutively expressed and are 60%
identical at the amino acid level. Both enzymes are regulated by
Ca2-mobi1izing agonists that trigger an increase in intracellular
free Ca2, which binds to calmodulin, and thus activates NO
synthase [1, 2]. A third type of NO synthase has been cloned from
murine macrophages and proved to be 51% and 50% homologous
to the brain and endothelial enzymes, respectively [3, 4]. The
macrophage-type of NO synthase is not constitutively expressed,
but is induced by y-interferon and lipopolysaccharide, and is
Ca2-independent. The macrophage NO synthase is regulated on
a transcriptional level and once induced is active for hours and
days. Not surprisingly, therefore, the inducible macrophage en-
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zyme produces amounts of NO that are several hundred times
higher than the ones produced by the constitutive endothelial cell
and brain enzymes which are only active during the short periods
of elevated intracellular Ca2 observed after exposure of cells to
Ca2-mobilizing agonists [1, 2].
Glomerular mesangial cells are a specialized type of vascular
smooth muscle, so-called pericytes, which take part in the regu-
lation of the glomerular filtration rate [5, 6]. These cells respond
to endothelial-derived NO with increased levels of intracellular
cGMP and subsequent relaxation [7, 8]. In addition, mesangial
cells synthesize several inflammatory mediators such as growth
factors and cytokines and actively participate in the pathogenesis
of inflammatory glomerular injury [9, 10]. We and others have
shown that cytokines, such as IL-i and tumor necrosis factor a, or
lipopolysaccharide induce a NO synthase in mesangial cells with
subsequent elevation of cellular cGMP concentrations [11—13].
The excessive formation of NO and cGMP in mesangial cells not
only alters contractile responses of the cells [14], but may also
cause tissue injury and thus contribute to the pathogenesis of
certain forms of glomerulonephritis [15, 16]. As in smooth muscle
cells [17] the NO synthase expressed in mesangial cells in response
to cytokine stimulation resembles the macrophage-type enzyme
[14]. NO synthase is completely dependent on the presence of
L-arginine and NADPH, is weakly enhanced by exogenous BH4
and is not significantly affected by Ca2 and calmodulin [14].
When mesangial cell NO synthase is partially purified by affinity
chromatography on ADP-agarose to remove the endogenous
BH4, the purified enzyme depends to 70% on addition of this
compound [14]. Moreover, IL-1j3 and tumor necrosis factor a
markedly increase the mRNA levels of the inducible macrophage
form of NO synthase in mesangial cells, whereas control cells, not
exposed to cytokines, do not display detectable levels of NO
synthase mRNA [18].
Biosynthesis of BH4 occurs via two distinct pathways: a de novo
pathway which uses GTP as a substrate and a salvage pathway
using the intracellular pool of pre-existing dihydropterins as
depicted in Figure 1 [19, 20]. Cytokines like y-interferon or tumor
necrosis factor a have been reported to potently stimulate the de
novo synthesis of BH4 in human and murine macrophages,
fibroblasts and endothelial cells [20]. This increased production of
BH4 may be required in order to ensure a sufficient supply of
cofactor for long-term synthesis of NO via the inducible macroph-
age-type NO synthase [21].
The present paper addresses the impact of BH4 supply in
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Fig. 1. Schematic depiction of the enzymatic pathways for biosynthesis of
BH GTP cyclohydrolase I catalyzes the initial reaction in de novo
synthesis of BH4. In the salvage pathway, sepiapterin is converted to BH4
by the sequential action of sepiapterin reductase and dihydrofolate
reductase. H2NTP, dihydroneopterin triphosphate; 6PPH4, 6-pyruvoyltet-
rahydropterin; BH4; tetrahydrobiopterin; DAHP, 2,4-diamino-6-hydroxy-
pyrimidine; NAS, N-acetylserotonin; MTX, methotrexate.
cytokine-stimulated giomerular mesangial cells. We provide evi-
dence that the endogenous synthesis of BH4 limits the synthesis of
NO in mesangial cells exposed to IL-lp. Pharmacological modu-
lation of endogenous BH4 levels may provide new therapeutic
approaches for the treatment of inflammatory reactions associ-
ated with high NO output.
Part of this material was presented in abstract form at the 25th
Annual Meeting of the Swiss Societies of Experimental Biology in
Bern [22].
Methods
Cell culture
Rat glomerular mesangial cells were cultured as described
previously [23]. In a second step, single cells were cloned by
limited dilution using 96-micro-well plates. Clones with apparent
mesangial cell morphology were used for further processing. The
cells exhibited the typical stellate morphology. Moreover, there
was positive staining for the intermediate filaments desmin and
vimentin, which are considered to be specific for myogenic cells,
positive staining for Thy 1.1 antigen, negative staining for factor
Vill-related antigen and cytokeratin excluded endothelial and
epithelial contaminations, respectively. The generation of inositol
trisphosphate upon activation of the angiotensin II AT1 receptor
was used as a functional criterion for characterizing the cloned
cell line [24]. The cells were grown in RPMI 1640 supplemented
with 10% fetal calf serum, penicillin (100 U/mi), streptomycin
(100 g/ml) and bovine insulin at 0.66 U/ml (Sigma). For the
experiments passages 8 to 15 were used. Confluent mesangial cells
in 24-well plates (16 mm diameter wells) were incubated with the
indicated concentrations of compounds in Dulbecco's modified
Eagle's medium (DMEM) without phenol red containing 0.1
mg/mI of bovine serum albumin for 24 hours. Thereafter, the
medium was removed for determination of nitrite concentration.
Cell protein determination was performed according to the
method of Lowry et al [25] with bovine serum albumin (Sigma) as
standard.
Nitrite analysis
Nitrite production by rat glomerular mesangial cells was mea-
sured by the Griess reaction as described previously [26]. After
stimulation the medium was withdrawn and centrifuged for 10
minutes at 6000 rpm in an Eppendorf-iab centrifuge. Nitrite was
measured by mixing 150 j.tl of the supematant with an equal
volume of Griess reagent. The absorbance at 550 mm was
measured and the nitrite concentration was determined using a
calibration curve with sodium nitrite standards.
cGMP determination
Confluent mesangial cells in 35 mm diameter dishes were
preincubated with IL-113 together with the different compounds
for the indicated time periods. Thereafter, the medium was
removed and the cells were rinsed twice and incubated for an
additional 10 minutes in the presence of the phosphodiesterase
inhibitor 3-isobutyl 1-methylxanthine (0.5 mM). The reaction was
terminated by aspiration of the medium and addition of 1 ml
ice-cold 5% (wt/vol) trichioroacetic acid. For extraction of cGMP
the dishes were put on ice for one hour. The trichloroacetic acid
was then removed by three extractions with 10 X volume of
water-saturated diethyl ether, and cGMP was determined by
radioimmunoassay (New England Nuclear).
Chemicals
Recombinant human IL-1/3 was supplied by Dr. Klaus Vosbeck,
Ciba-Geigy Ltd. (Basel, Switzerland); methotrexate, N-acetyl
serotonin and 2,4-diamino-6-hydroxypyrimidine were from Sigma
(Buchs, Switzerland); sepiapterin, pterin-6-carbocylic acid, isox-
anthopterin were purchased from Dr. B. Schirks Laboratories
(Jona, Switzerland); cell culture media and nutrients were from
Gibco BRL (Basel, Switzerland); and all other chemicals were
either from Merck (Darmstadt, Germany) or Fluka (Buchs,
Switzerland).
Results
Incubation of mesangial cells for 24 hours with IL-113 (2 nM)
stimulates the synthesis of nitrite (Fig. 2A), a stable end product
of cellular NO formation, and increases the concentration of
intracellular cGMP (Fig. 2B), well in agreement with previous
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Fig. 2. Inhibition of interleukin 1(3-stimulated
nitrite (A) and cUMP (B) production in
mesangial cells by DAHP. Mesangial cells were
incubated for 24 hours with vehicle (Con),
interleukin 1(3 (IL-i, 2 nM) or interleukin 1/3
plus the indicated concentrations of DAHP.
Thereafter, the medium was removed and
used for nitrite determination (A). cGMP was
determined as described in the Methods
section (B). Results are means so for 4
experiments.
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Fig. 3. Sepiapterin effects on IL-1/3-stimulated nitrite production in mesang-
ial cells. Mesangial cells were incubated for 24 hours with vehicle (Con),
interleukin 1/3 (IL-i, 1 nM) or interleukin 1(3 plus DAHP (1 mM) or
sepiapterin (Sep, 100 jLM) as indicated. Thereafter, the medium was
removed and used for nitrite determination. Results are means SD for
4 experiments.
studies [ii, 14, 18]. To address the requirement for BH4 in the
IL-1/3-stimulated NO production, we incubated mesangial cells
with DAHP, a competitive inhibitor of GTP cyelohydrolase I, the
rate-limiting enzyme in the biosynthetic pathway of BH4 (Fig. 1)
[27]. We found that treatment of mesangial cells with DAHP
dose-dependently prevented IL-1fl-induced nitrite production
(Fig. 2A) as well as cGMP elevations (Fig. 2B). Half-maximal
inhibition of IL-1/3-stimulated nitrite and cGMP formation are
observed at 0.49 m and 0.48 mivi DAHP, respectively. DAHP has
no effect on sodium nitroprusside-stimulated guanylate cyclase
activity (data not shown), thus suggesting that the compound
affects NO synthesis rather than cOMP formation itself. Addition
of sepiapterin (100 jxM), which is intracellularly converted into
BH4 via the dihydrofolate reductase-dependent pterin salvage
pathway as depicted in Figure 1 [19, 20], completely reverses the
inhibitory action of DAHP on nitrite production, as shown in
Figure 3. Inhibition by DAHP is not overcome by uneonjugated
pteridines such as pterin-6-carbocylic acid and isoxanthopterin,
which cannot be converted to BH4 [19] (data not shown). In the
absence of DAHP, sepiapterin potentiates the IL-l(3-stimulated
nitrite production as shown in Figure 3. At a concentration of 100
.tM, sepiapterin augmented cytokine-induced nitrite generation by
more than threefold (Fig. 3).
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Fig. 4. Inhibition of interleukin 1(3-stimulated nitrite production by N-
acetylserotonin. Mesangial cells were incubated for 20 hours with vehicle
(Con), interleukin 1/3 (IL-i, 2 nM) or interleukin 1/3 plus the indicated
concentrations of N-aeetylserotonin (NAS). Thereafter, the medium was
removed and used for nitrite determination. Results are means 5D for
4 experiments.
Another inhibitor that blocks BH4 biosynthesis in cells is
N-acetylserotonin which selectively inhibits sepiapterin reductase
(Fig. 1) [28]. N-acetylserotonin has been used to deplete cellular
levels of BH4 in several systems [28—30]. As shown in Figure 4,
N-acetylserotonin concentration-dependently suppresses IL-1/3-
stimulated nitrite production in mesangial cells. Half maximal
inhibition is observed at 0.25 mrvi N-acetylserotonin. Finally, we
examined the effects of methotrexate which interferes with BH4
synthesis via the salvage pathway by specifically blocking dihydro-
folate reductase (Fig. 1) [19]. Methotrexate only slightly attenu-
ates IL-i (3-stimulated nitrite production to a maximal extent of
approximately 30% (Fig. 5). As compared with untreated control
cells, a 24 hour treatment of mesangial cells with 100 MM
sepiapterin, 5 mM DA}IP, 5 mivi N-acetylserotonin, 10 gM meth-
otrexate, 2 n IL-1/3 or combinations of the different agents does
not affect cell viability as determined with a sensitive dye-uptake
assay [31].
Discussion
In activated macrophages y-interferon and lipopolysaccharide
trigger the expression of an inducible type of NO synthase which
produces high amounts of the unstable and extremely reactive gas
NO. NO is suggested to account, at least in part, for the killing of
bacteria, protozoa, fungi and tumor cells by activated macro-
phages [1]. We have demonstrated that inflammatory cytokines
such as IL-i$ or tumor necrosis factor a induce the expression of
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Fig. S. Inhibition of interleukin 113-stimulated nitrite production by metho-
trexate. Mesangial cells were incubated for 20 hours with vehicle (Con),
interleukin 13 (IL-i, 2 nM) or interleukin 1 plus methotrexate (MTX, 10
LM). Thereafter, the medium was removed and used for nitrite determi-
nation. Results are means SD for 4 experiments.
a Ca2-independent macrophage-type of NO synthase in rat
glomerular mesangial cells that produces tremendous amount of
NO [14, 18]. It seems quite possible that the excessive production
of NO may provide mesangial cells with properties that make
them partially act as macrophages and thus contribute to tissue
injury observed in certain forms of glomerulonephritis [15, 16].
This hypothesis gains support from recent observations showing
that anti-inflammatory steroids [11, 32], transforming growth
factors of the 13-type [12, 23], platelet-derived growth factor [33]
and the immunosuppressive drug cyclosporin A [18] potently
suppress cytokine-induced NO synthase expression in mesangial
cells. The inhibition of cytokine induction of NO synthase may be
one aspect of the beneficial action of glucocorticoids and cyclo-
sporin A seen in certain renal diseases.
Moreover, at the same time, NO causes relaxation of the
contractile mesangial cells [7, 14] and thus leads to a state of
glomerular hyperifitration. This condition seems to be an impor-
tant pathogenetic mechanism for the development of glomerular
sclerosis. Cattell et al [34] and Cook and Sullivan [35] have shown
that glomeruli isolated from rats with experimental nephrotoxic
nephritis or in situ immune complex glomerulonephritis produce
nitrite. This synthesis of nitrite was spontaneous and further
increased by treatment with lipopolysaccharide. Dexamethasone
potently suppressed nitrite production in endotoxin-treated gb-
meruli. Furthermore, nitrite generation was also observed in
glomeruli isolated from rats with active Heymann nephritis, a
model of membranous glomerulonephritis [36], and in the Thy 1.1
model of mesangial proliferative glomerulonephritis [37]. These
data suggest that in several models of experimental glomerulone-
phritis the formation of NO is increased to micromolar levels, due
to the induction of a macrophage-type of NO synthase in infil-
trating macrophages as well as in resident mesangial cells. Fur-
thermore, glomerular NO production has been implicated in the
pathomechanisms of proteinuria, thrombosis, leukocyte infiltra-
tion, matrix production, mesangial cell proliferation and local
immunosuppressive effects [15, 16]. Recently Weinberg et al [38]
reported that oral administration of NGmonomethylLarginine,
a NO synthase inhibitor, prevented the development of glomeru-
lonephritis and reduced the intensity of inflammatory arthritis in
MRL-lpr/lpr mice that develop a spontaneous autoimmune dis-
ease [39]. It is tempting to suggest that the regional or systemic
use of compounds that block the production of NO may be of
value in therapy of autoimmune and other inflammatory diseases.
This could be achieved by direct inhibitors of NO synthase such as
NGmonomethylLarginine or by agents that inhibit the action of
NO such as hemoglobin or myoglobin that scavenge free NO [1,
2]. However, these compounds will affect constitutive and induc-
ible NO synthases equally well and thus may lead to unwanted
side effects. In an alternative approach we have addressed in the
present report the role of the NO synthase cofactor BH4. BH4 is
the required cofactor for phenylalanine, tyrosine and tryptophan
hydroxylases and alkylglycerol monooxygenase [19]. Besides these
enzymes the cofactor role of BH4 is restricted to NO synthase and,
therefore, inhibition of BH4 synthesis will result in a very re-
stricted pattern of effects. Our results strongly suggest that
synthesis of BH4 is an essential requirement for induction of NO
synthase activity in mesangial cells. Inhibition of GTP cycbohydro-
lase I or sepiapterin reductase by DAHP or N-acetylserotonin,
respectively, potently prevents IL-113 induction of NO synthase
activity (Figs. 2 and 4). From these data it seems reasonable to
consider inhibitors of biopterin synthesis as a new pharmacolog-
ical approach applicable to conditions of pathological NO over-
production. In general, sepiapterin reductase inhibition will pro-
duce a more specific depletion of BH4 than would inhibition of
earlier reactions in the biosynthetic pathway of BH4. The thera-
peutic potential of BH4 synthesis inhibitors seems to be quite
promising as DAHP cannot pass the blood/brain barrier and,
therefore, does not interfere with the production of dopamine and
serotonin in the central nervous system [40]. Although inhibition
of BH4 synthesis does not produce acute inhibitory effects on the
constitutive endothelial cell NO synthase, chronic treatment with
DAHP has recently been shown to inhibit endothelial NO pro-
duction [41]. However, considering the enormous requirement of
BH4 during cytokine induction of NO synthase, it is obvious that
proper NO synthase function is crucially dependent on BH4
supply. Inhibition of BH4 synthesis may, therefore, result in a
quite selective suppression of inducible NO synthase activity. In
line with this view are the results depicted in Figure 3 that
demonstrate that the availability of BH4 is actually limiting the
activity of NO synthase in IL-i /3-stimulated mesangial cells.
Comparable data have been reported in rat vascular smooth
muscle cells [30], in murine macrophages [42], and in human
umbilical vein endothelial cells [43]. Thus, it seems that in the
presence of stimuli triggering the expression of inducible NO
synthase, the enzyme is not saturated with BH4, although the
cofactor's synthesis is enhanced in parallel [20]. In this context it
is worth mentioning that cytokines and cAMP elevating agents
synergize to trigger inducible NO synthase expression and nitrite
production in mesangial cells [44, 45] to levels far beyond those
achieved by IL-113 plus sepiapterin (Fig. 3). These observation
raise the possibility that synergistic induction of NO synthase
activity by IL-1/3 and cAMP may depend, at least in part, on a
combined effect not only on NO synthase expression, but also on
the enzymatic pathway necessary for BH4 synthesis. This hypoth-
esis is under evaluation in our laboratory.
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